Stockscreener 앱 받기
0.0001
33.64%
-0.0602
Paxmedica Inc 주식(PXMD)의 최신 뉴스
MorphoSys (NASDAQ:MOR) vs. PaxMedica (NASDAQ:PXMD) Head to Head Comparison - Defense World
Autism Spectrum Disorder Market to Reach USD 4.07 Billion - GlobeNewswire
PXMD Stock Institutional Owners - Quiver Quantitative
Plus Therapeutics Regains Compliance With Two Nasdaq Listing Rules - marketscreener.com
Contrasting Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & PaxMedica (NASDAQ:PXMD) - Defense World
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Comparing Intra-Cellular Therapies (NASDAQ:ITCI) and PaxMedica (NASDAQ:PXMD) - Defense World
Kuvatris Therapeutics Renames, Cancels Shares Amid Restructuring - AInvest
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica announces board resignations amid transition - Investing.com
PaxMedica Announces Board Chairman Resignation Amid Transition - TipRanks
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica Announces Resignation of Key Executives - TipRanks
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - ACCESS Newswire
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Immediate Exercise of Warrants - ACCESS Newswire
PaxMedica, Inc. (PXMD) Stock Price, News, Quote & History - Yahoo
PaxMedica Secures Groundbreaking China Patent for Autism Treatment Breakthrough After 100 Years - Stock Titan
Autism Prevalence Surges Globally, Raising Concerns Among Healthcare Experts - FinancialContent
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K | Dow Theory Letters - FinancialContent
Autism Spectrum Disorder Therapeutics Market size is set to grow by USD 766.1 million from 2024-2028, Increasing prevalence of asd to boost the market growth, Technavio - PR Newswire
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones - FinancialContent
Researchers Say Brain ‘Overgrowth’ Could Contribute to Autism Development - FinancialContent
Silicon Valley - FinancialContent
PaxMedica (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher - Barchart.com
PaxMedica (PXMD) Stock Trends and Sentiment 2025 - MarketBeat
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments - FinancialContent
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
Cardio Diagnostics Holdings, Inc. (CDIO) stock price, news, quote and history - Yahoo! Finance Singapore
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView — Track All Markets
PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA - FinancialContent
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - GlobeNewswire
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
Malawi’s Health Ministry Seeks Emergency Access to PaxMedica’s IV Suramin - NAVLIN DAILY
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Up 93% Today? - InvestorPlace
PaxMedica Achieves Key Milestone in the Development of - GlobeNewswire
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica Accelerates RSU Vesting for Top Executives - TipRanks
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
Ocean Biomedical, Inc. (OCEA) options chain - Yahoo! Finance Singapore
HC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy Recommendation - Nasdaq
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
Penny Stocks To Buy? 5 To Watch Right Now - PennyStocks.com
PaxMedica, Inc. (PXMD) latest stock news and headlines - Yahoo Finance UK
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Down 40% Today? - TradingView — Track All Markets
Virax Biolabs Group Limited (VRAX) stock price, news, quote and history - Yahoo! Finance Singapore
PaxMedica Releases Q3 2023 Financial Report, Corporate Update - Yahoo Finance
What LIFW, PXMD, and NVOS have in common - StocksToTrade
PaxMedica Surges After Publication Of Statistically Significant Data From Its Autism Spectrum Study - Nasdaq
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV) - FinancialContent
PaxMedica buys research assets to support PAX-101 FDA application (PXMD) - Seeking Alpha
Thinking about buying stock in Nextplay Technologies, ABVC Biopharma, PaxMedica, Mustang Bio, or NXU Inc.? - MarketScreener
PaxMedica stock soars 110% on FDA update for lead drug PAX-101 (PXMD) - Seeking Alpha
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD) - Yahoo Finance
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 - Yahoo Finance
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update - Yahoo Finance
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301 - Yahoo Finance
PaxMedica Comments on Common Stock Volatility - Yahoo Finance
PaxMedica CEO Interviewed by The BRAIN Foundation - Yahoo Finance
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - Clinical Trials Arena
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder - Yahoo Finance
PaxMedica and PoloMar to investigate emodin in ASD trial - Clinical Trials Arena
PaxMedica Enters Research Collaboration Agreement With - GlobeNewswire
PaxMedica Completes HAT-301 Registrational Trial for PAX-101 - GlobeNewswire
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 - Yahoo Finance
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results - Yahoo Finance
Autistic Disorder Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - Yahoo Finance
PaxMedica Awaits HAT Trial Data - RTTNews
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event - Yahoo Finance
2.92%
2.36%
자본화:
|
볼륨(24시간):